Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib in NSCLC with Uncommon EGFR Mutations
NCT05277701Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Status: unknown.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05277701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277701.